Table 1.

Projected worldwide health consequences of blood pressure intervention scenarios

	Business as usual (2020)	Business as usual (2050)	Progress (2050)			Aspirational (2050)
			Sodium reduction	Hypertension treatment	Both interventions	Sodium reduction	Hypertension treatment	Both interventions
Number of CVD deaths (millions)	17	37	36	33	33	36	30	29
Difference	-	-	−1.9%	−11%	−13%	−3.7%	−20%	−22%
Number of all-cause deaths (millions)	50	82	81	79	79	81	76	76
Difference	-	-	−0.57%	−3.4%	−3.8%	−1.1%	−6.3%	−6.8%
Number of new CVD cases (millions)	35	76	74	71	70	73	67	66
Difference	-	-	−1.7%	−5.8%	−7.1%	−3.3%	−11%	−13%
Number of prevalent CVD cases (millions)	320	710	700	690	680	690	670	660
Difference	-	-	−1.9%	−2.8%	−4.3%	−3.7%	−5.5%	−7.8%
Life expectancy at birth (years)	73	78	78	78	78	78	79	79
Difference	-	-	0.11%	0.70%	0.78%	0.22%	1.2%	1.3%
Probability of dying between 30 years and 80 years of age from CVD	0.20	0.18	0.18	0.15	0.15	0.17	0.14	0.13
Difference	-	-	−2.3%	−14%	−16%	−4.5%	−24%	−26%

Aggregate estimates of the effect of improved blood pressure control in 182 countries. Results are based on estimates of CVD deaths and cases across all age groups (20+ years) and both sexes. For the purpose of reporting the results in this table, the effects of sodium reduction and hypertension treatment were modeled separately and then together (‘both interventions’). The difference reported is the relative difference of the intevention scenario compared to the business-as-usual projections for 2050.